Safety of Moxifloxacin as Shown in Animal and In Vitro Studies

作者
David H. McGee,William F. Holt,Philip R. Kastner,Rebecca L. Rice
出处
期刊:Survey of Ophthalmology [Elsevier]
卷期号:50 (6): S46-S54 被引量:30
标识
DOI:10.1016/j.survophthal.2005.05.003
摘要

Topical treatment of ocular bacterial infection is practiced widely, and the choice of the antibacterial agent depends on the nature of the infection, including the susceptibility of the organism, the tissue affected, and the safety profile of the agent. Moxifloxacin is a fourth-generation fluoroquinolone approved for ophthalmic use as moxifloxacin ophthalmic solution 0.5% (VIGAMOX, Alcon, Fort Worth, TX). Moxifloxacin ophthalmic solution 0.5% is self-preserved at a near-neutral pH of 6.8. In treating ocular infection, the three important aspects of therapeutic control are potency, penetration of the drug to the target site, and safety of the drug and the drug product. Moxifloxacin ophthalmic solution 0.5% provides antibacterial potency and high penetration of target ocular tissues. The ocular and systemic safety profile of moxifloxacin compares favorably with those of other fluoroquinolone antimicrobial agents, with a low risk of recognized quinolone-related toxicity. In vitro studies of fluoroquinolones with human or rabbit corneal epithelial cells or keratocytes suggest that moxifloxacin is similar in cytotoxicity potential to other drugs of this family. Specialized in vivo corneal wound-healing studies draw little distinction between moxifloxacin-treated eyes and those treated with other fluoroquinolones. Repeated-dose topical ocular studies in rabbits and monkeys, with high concentrations (up to 3%) of moxifloxacin and at treatment durations and regimens well in excess of label-prescribed use, demonstrated a high safety margin for ocular and extraocular tissues. Cornea, the tissue with highest exposure, was found to be unaffected by these high exposures, with slit-lamp biomicroscopy, corneal thickness measurement, intraocular pressure, and specular microscopy of the corneal endothelium (monkeys only), and histologic evaluation showing no effects, as compared with controls. Moxifloxacin ophthalmic solution 0.5% affords superior efficacy and ocular tissue penetration, with a favorable safety profile.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
建议保存本图,每天支付宝扫一扫(相册选取)领红包
实时播报
1秒前
复杂的问丝完成签到,获得积分10
1秒前
张文发布了新的文献求助10
1秒前
xixi发布了新的文献求助10
2秒前
4秒前
大个应助Sun采纳,获得10
4秒前
5秒前
777567完成签到,获得积分10
5秒前
5秒前
6秒前
Jiaxing发布了新的文献求助10
6秒前
7秒前
zzz发布了新的文献求助10
8秒前
沉静的剑身完成签到,获得积分10
8秒前
镓氧锌钇铀应助禾伙人采纳,获得20
9秒前
sylvia发布了新的文献求助30
9秒前
所所应助自由一一采纳,获得10
10秒前
peter完成签到,获得积分10
11秒前
李大白发布了新的文献求助10
12秒前
12秒前
13秒前
Funniu发布了新的文献求助10
13秒前
14秒前
xixi完成签到,获得积分10
14秒前
单于天宇完成签到,获得积分10
14秒前
14秒前
三人水明完成签到 ,获得积分0
14秒前
cslghe完成签到,获得积分10
15秒前
15秒前
何禾完成签到 ,获得积分10
15秒前
16秒前
JamesPei应助牛马采纳,获得10
18秒前
CipherSage应助zzz采纳,获得10
18秒前
19秒前
王文艺发布了新的文献求助30
19秒前
Frank应助科研通管家采纳,获得10
20秒前
在水一方应助科研通管家采纳,获得10
20秒前
小二郎应助科研通管家采纳,获得10
20秒前
华仔应助科研通管家采纳,获得10
20秒前
Hello应助科研通管家采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Mentoring for Wellbeing in Schools 1200
List of 1,091 Public Pension Profiles by Region 1061
Binary Alloy Phase Diagrams, 2nd Edition 600
Atlas of Liver Pathology: A Pattern-Based Approach 500
A Technologist’s Guide to Performing Sleep Studies 500
EEG in Childhood Epilepsy: Initial Presentation & Long-Term Follow-Up 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5497239
求助须知:如何正确求助?哪些是违规求助? 4594744
关于积分的说明 14446447
捐赠科研通 4527478
什么是DOI,文献DOI怎么找? 2480884
邀请新用户注册赠送积分活动 1465248
关于科研通互助平台的介绍 1437903